p16, p53 and EGFR expression in head and neck squamous cell carcinoma and their correlation with clinicopathological parameters.

Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-4138 (Electronic) Linking ISSN: 19984138 NLM ISO Abbreviation: J Cancer Res Ther Subsets: MEDLINE

Original Publication: Mumbai, India : Medknow Publications

ErbB Receptors*/metabolism ; ErbB Receptors*/genetics ; Tumor Suppressor Protein p53*/metabolism ; Tumor Suppressor Protein p53*/genetics ; Cyclin-Dependent Kinase Inhibitor p16*/metabolism ; Cyclin-Dependent Kinase Inhibitor p16*/genetics ; Squamous Cell Carcinoma of Head and Neck*/pathology ; Squamous Cell Carcinoma of Head and Neck*/virology ; Squamous Cell Carcinoma of Head and Neck*/metabolism ; Squamous Cell Carcinoma of Head and Neck*/mortality ; Squamous Cell Carcinoma of Head and Neck*/genetics ; Head and Neck Neoplasms*/pathology ; Head and Neck Neoplasms*/metabolism ; Head and Neck Neoplasms*/virology ; Head and Neck Neoplasms*/genetics ; Biomarkers, Tumor*/metabolism ; Biomarkers, Tumor*/genetics; Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Cross-Sectional Studies ; Papillomavirus Infections/complications ; Papillomavirus Infections/virology ; Papillomavirus Infections/pathology ; Papillomavirus Infections/metabolism ; Immunohistochemistry ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/virology ; Carcinoma, Squamous Cell/genetics ; Prognosis

Introduction: Oral squamous cell carcinoma is a major cause of death throughout the developed world. Human papillomavirus (HPV) type 16 has also been suggested to play a role in etiology of head and neck squamous cell carcinoma (HNSCC). p16 expression is now being used as a surrogate marker of HPV infection in squamous cell carcinoma. Dysfunction in the p53 tumor suppressor gene is implicated in many cancers, including head and neck cancer. Overexpression or mutation of EGFR is found in 80%-100% of the patients with HNSCC, and is associated with poor prognosis and decreased survival.
Materials and Methods: In this cross-sectional observation study, total of 100 cases of HNSCC were taken. p16, p53, and EGFR expression was determined by immunohistochemical staining and correlated with clinicopathological parameters. p16 expression was also correlated with expression of p53 and EGFR. The obtained results were analyzed and evaluated using Chi-square test, value of P < 0.05 was taken significant.
Results: p16, p53, and EGFR were positive in 60%, 44%, and 58% cases, respectively. A statistically significant association was observed between p16 with age, site of the tumor, abnormal sexual habits and lymph node involvement. Significant expression also seen between p53 with age and abnormal sexual habits and immunohistochemical expression of p16 with p53 and EGFR.
Conclusion: Immunohistochemical expression of p16 can be used as a surrogate marker of HPV. Study of p16, p53, and EGFR expression may provide clinicians with more exact information in order to evaluate tumor aggressiveness and treatment modalities.
(Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.)

Elango JK, Gangadharan P, Sumithra S, Kuriakose MA. Trends of head and neck cancers in urban and rural India. Asian Pac J Cancer Prev 2006; 7:108–12.
Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. BCL-x and bcl2, p53 expression in squamous cell carcinoma of the head and neck cancer. Cancer 1999; 85:164–70.
Hennessey PT, Westra WH, Califano JA. Human papillomavirus and head and neck squamous cell carcinoma: Recent evidence and clinical implications. J Dent Res 2009; 88:300–6.
Syrajanen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol 2010; 21:243–5.
Vairaktaris E, Yapijakis C, Psyrri A, Spyridonidou S, Yannopoulos A, Lazaris A, et al. Loss of tumor suppressor p16 expression in initial stages of oral oncogenesis. Anticancer Res 2007; 27:979–84.
Strickler TP, Kumar V. Neoplasia Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Saunders; 2011;259–330.
Abusail MS, Dirweesh AMA, Salih RAA, Gadelkarim AH. Expression of EGFR and p53 in head and neck tumors among Sudanese patients. Asian Pac J Cancer Prev 2013; 14:6415–18.
Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization classification of tumours. Pathology and Genetics of Head and Neck Tumours 11. France, Lyon: IARC Press; 2005;1–15.
Fregonesi PA, Teresa DB, Duarte RA, Neto CB, Oliveira M, Soares CP. p16ink4a immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem 2010; 51:1291–7.
Solomon MC, Carnelio S, Gudattu V. Molecular analysis of oral squamous cell carcinoma: A tissue microarray study. Indian J Cancer 2010; 47:166–72.
Yuen AP, Lam KY, Choy JT, Ho WK, Wong LY, Wei WI. Clinicopathologic significance of bcl-2 expression in the surgical treatment of oral squamous cell carcinoma. J Surg Oncol 2002; 94:713–22.
Afriyie OO, Owiredu WKBA, Danquah KO, Reindorf RL. Expression of immunohistochemical markers in non-oropharyngeal head and neck squamous cell carcinoma in Ghana. Pone 2018; 59:711–5.
Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschim L, Porfirio B. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J of Cancer 1999; 84:573–79.
Ralli M, Singh S, Yadav SPS, Sharma N, Verma R, Sen R. Assessment and clinicopathological correlation of p16 expression in head and neck squamous cell carcinoma. J Cancer Res Ther 2016; 12:232–37.
Shinohara S, Kikuchi M, Kanazawa Y, Kishimoto I, Harada H, Imai Y, et al. Prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas. Jap J Clin Oncol 2014; 44:232–40.
Simsek G, Han U, Onal B, Koybasioglu F, Akin I, Dagli M. Expression of cyclin D1, p27, p21, bcl2 and p53 in laryngeal squamous cell carcinoma and an investigation of the correlation with the conventional prognostic factors. Turk J Med Sci 2013; 43:27–32.
Sweeny L, Dean NR, Magnuson JS, Carroll WR, Helman EE, Hyde SO, et al. EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck 2012; 34:681–6.
Dalal V, Alam K, Maheshwari V, Sharma S C, Jain A, Khan R. Correlation of clinicopathological parameters with EGFR and Her-2 neu status in oral cancer patients in a tertiary care centre. Int J Biomed Res 2015; 6:897–902.
Dragomir LP, Simionescu C, Margaritescu CI, Stepan A, Dragomir IM, Popescu MR. p53, p16 and Ki-67 immunoexpression in oral squamous carcinomas. Rom J Morphol Embryol 2012; 53:89–93.
Pannone G, Rodolico V, Santoro A, Muzio L, Franco R, Botti G, et al. Evaluation of combined triple method to detect causative HPV in oral and oropharyngeal carcinomas: p16 immunohistochemistry, consensus PCR HPV-DNA, and in situ hybridization. Infect Agents Cancer 2012; 7:4–17.
Lassaletta L, Brandariz J, Benito A, Cruz J, Gomez C, Ballestio C, et al. p53 expression in locally advanced pharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1999; 125:1356–59.
Karpathiou G, Monaya A, Forest F, Froudarakis M, Casteillo F, Marc Dumollard J, et al. p16 and p53 expression status in head and neck squamous cell carcinoma: A correlation with histological, histoprognostic and clinical parameters. J Pathol 2016; 48:341–8.
Condon L, Ashman J, Ell Stephen, Stafford N, Greenman J, Cawkwell L. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: A marker of radioresistance. Int J Cancer 2002; 100:472–5.
Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, et al. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope 2012; 122:2762–8.
Young R, Rischin D, Fisher R, McArthur GA, Fox SB, Peters LJ, et al. Relationship between epidermal growth factor receptor status, p16INK4A and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 20:1230–7.

EC 2.7.10.1 (ErbB Receptors)
0 (Tumor Suppressor Protein p53)
0 (Cyclin-Dependent Kinase Inhibitor p16)
EC 2.7.10.1 (EGFR protein, human)
0 (Biomarkers, Tumor)
0 (TP53 protein, human)
0 (CDKN2A protein, human)

Date Created: 20240718 Date Completed: 20240718 Latest Revision: 20240718

20240718

10.4103/jcrt.JCRT_201_20

39023595